COVID-19 TOWN HALL

May 20th, 2020
BOARD OF PHARMACY UPDATE

- FAQ’S
- Submit ?’s

Arizona State Board of Pharmacy
Protects the health, safety and welfare of the citizens of Arizona

COVID-19 QUESTIONS
Click here to ask a question concerning COVID-19

COVID-19 Information and Updates
Submit COVID-19 Questions
COVID-19 FAQs updated 4/23/20 (as situations progress, the FAQ will continue to change and be revised). Please check the ASBP website for updates.

Governor Ducey’s Executive Order - Expanding Access to Pharmacies (see updated FAQs)
State and National Updates

Kelly Fine
Executive Director | Arizona Pharmacy Association
### Summary

Select a county to filter the other numbers.
Deaths will not be shown for counties with fewer than three deaths.

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Cases</td>
<td>14,566</td>
</tr>
<tr>
<td>Number of Deaths</td>
<td>704</td>
</tr>
<tr>
<td>Number of COVID-19 Tests</td>
<td>220,612</td>
</tr>
<tr>
<td>Number of New Cases reported today*</td>
<td>396</td>
</tr>
<tr>
<td>Number of New Deaths reported today*</td>
<td>18</td>
</tr>
<tr>
<td>Number of New Tests reported today*</td>
<td>7,828</td>
</tr>
<tr>
<td>Rate of cases, per 100,000 population</td>
<td>202.6</td>
</tr>
<tr>
<td>Rate of fatalities, per 100,000 population</td>
<td>9.79</td>
</tr>
<tr>
<td>Total Percent Positive**</td>
<td>5.9%</td>
</tr>
<tr>
<td>Total COVID-19 PCR Tests</td>
<td>161,571</td>
</tr>
<tr>
<td>New PCR Tests reported today*</td>
<td>5,090</td>
</tr>
<tr>
<td>PCR Percent Positive**</td>
<td>6.9%</td>
</tr>
<tr>
<td>Total COVID-19 Serology Tests</td>
<td>99,041</td>
</tr>
<tr>
<td>New Serology Tests reported today*</td>
<td>2,730</td>
</tr>
<tr>
<td>Serology Percent Positive**</td>
<td>3.1%</td>
</tr>
</tbody>
</table>

*Counts of new cases, deaths, and numbers tested reflect increases in the total numbers compared to the previous day.

**Percent positive is the number of people with a positive test result, out of all people with COVID-19 testing completed in AZ.
Returning Stronger
Data show Arizona is ready for a gradual and phased-in return.  PHASE 1

DECLINING SYMPTOMS

Hospital visits for 
COVID-like Illness (CLI) & 
Influenza-like Illness (ILI) 
are declining.

DECLINING PERCENTAGE OF POSITIVE TESTS

As the number of COVID-19 
diagnostic tests has 
increased, the percentage 
of positive tests has 
decreased.

TREAT ALL PATIENTS 
WITHOUT CRISIS CARE

- 1,405 healthcare providers with 
adequate PPE, including 51 
hospitals
- Adequate hospital beds, ICU 
beds and ventilators

ROBUST TESTING FOR 
AT-RISK HEALTHCARE 
WORKERS

- 51 hospitals attesting to a 
robust testing plan
- Implementing COVID-19 testing 
for residents and staff of 147 
long-term care facilities
- Tens of thousands of serology 
tests reported to ADHS

ARIZONA DEPARTMENT 
OF HEALTH SERVICES
What does this mean?
The US Health and Human Services (HHS) issued an advisory opinion yesterday concluding that licensed pharmacists may order and administer COVID-19 tests. This confirms the Administration’s intent and confidence in pharmacists to provide expanded and widespread testing capacity for Americans across the entire country. We are still evaluating the opinion and how this impacts pharmacists’ payment and billing for COVID-19 tests.

**At this time we do know:**
- You will need a CLIA Waiver
- NPI number (good idea if you plan to continue to do POC tests)
- You may need to apply as Independent Clinical Lab through Medicare
The House of Representatives reconvene on Tuesday, May 19\textsuperscript{th}

- Note: Bills cannot be amended because any SBs that get amended in the House have to go back to the Senate for final read and the Senate has indicated that they will not vote bills (other than perhaps the liability protection issue or a few third reads they may have ready to go).

- At this time, the Senate does not plan to reconvene this week but that is subject to change.
PLEASE NOTE: PPE (masks) is required in committee hearing rooms for members, staff, and guests.

Upon entering the building, you will see signage conveying the following messages: **BY ENTERING THE HOUSE OF REPRESENTATIVES BUILDING, YOU ARE AGREEING TO ABIDE BY THE HOUSE'S CDC-BASED GUIDELINES. YOU MAY BE ASKED TO LEAVE IF YOU FAIL TO ABIDE BY THE GUIDELINES.**

**STAY SAFE AND HEALTHY**

- PROTECT YOURSELF & OTHERS FROM THE SPREAD OF COVID-19. PLEASE FOLLOW THESE HOUSE OF REPRESENTATIVES SAFETY GUIDELINES:
  - If you are feeling sick, please do not enter the building. (Everyone will have their temperature taken upon entry)
  - PPE is expected to be worn by everyone. (PPE is available by request)
  - Strict social distancing is required. (Maintain six feet apart from others)
  - Only 2 people may enter an elevator at any one time
  - Wash your hands with soap and/or use hand sanitizer regularly
  - Cover your cough and sneeze and avoid touching your face
Emerging Condition: Possible Kawasaki Disease-like Syndrome Associated with COVID-19

A **pediatric multi-system inflammatory syndrome** has recently been reported in the UK and NYC that may be linked to COVID-19.

- Clinical features of this syndrome have been noted to include features of Kawasaki disease or shock; persistent fever and elevated inflammatory markers such as CRP and troponin have been seen among affected patients. Many of these children have tested positive either for COVID-19 or for its antibodies.

**If the above-described inflammatory syndrome is suspected, Arizona providers should immediately:**

- **Refer patients to a specialist.** (pediatric infectious disease, rheumatology, and/or critical care) Early diagnosis and treatment of patients meeting full or partial criteria for Kawasaki disease is critical to preventing end-organ damage and other long-term complications. Patients meeting criteria for Kawasaki disease should be treated with intravenous immunoglobulin and aspirin.

- **Consider COVID-19 testing.** Many pediatric patients with this syndrome did not show respiratory symptoms, yet tested positive for COVID-19 or its antibodies.

- **Report suspected cases of Kawasaki Disease-like Syndrome to local public health.** Real-time surveillance of this is critical to public health understanding and recommendations.
Update: Residency Licensure Requirements

Q: My incoming resident is having difficulty scheduling licensing exams. Test dates are already scheduled through September 2020. Is the Commission on Credentialing going to consider any actions to assist incoming residents who are having difficulty testing?

A: The Commission on Credentialing and ASHP Board of Directors approved a temporary waiver and extension of the licensure requirement for residents until January 1, 2021. This temporary waiver is for the requirement that residents complete at least two-thirds (2/3) of the residency year as a licensed pharmacist. This waiver is only for the 2020-2021 residency year.

PLEASE NOTE: Incoming residents are expected to schedule and take all required licensing exams at the earliest date possible.
The FDA has received 15 adverse event reports about the Abbott ID NOW device that suggest some users are receiving inaccurate negative results. The agency is reviewing these reports.

This test can still be used and can correctly identify many positive cases in minutes. Negative results may need to be confirmed with a high-sensitivity authorized molecular test.

Abbott has agreed to conduct post-market studies for the ID NOW device that each will include at least 150 COVID-19 positive patients in a variety of clinical settings. The FDA will continue to review interim data on an ongoing basis.
FDA Clears Standalone At-Home Collection Kit

COVID-19 Test Home Collection Kit

Diagnose whether you are infected with SARS-CoV-2. The Everlywell COVID-19 Test Home Collection Kit and our lab partners have received Emergency Use Authorization from the FDA. After an online screening, you can collect your sample and send it for processing to a certified lab for secure digital results within days. A telehealth consult is available to guide you through your next steps.

Measures
Presence or absence of RNA from SARS-CoV-2 virus

Collection Method
1 Self-collected nasal swab

Available results in
3-5 days from purchase (overnight shipping to the lab is included)

COVID-19 Test Home Collection Kit $109
Check Availability
On May 14th the FDA issued an update to its guidance for pharmacy compounders that experience shortages, due to the COVID-19 public health emergency, of the (PPE) they typically use to compound sterile drugs.

The FDA clarified that drugs can be compounded in a segregated compounding area that is not in a cleanroom, when the following BUD are utilized:

- Up to 12 hours for product stored at room temp
- Up to 24 hours for refrigerated products
The horizontal dotted lines with risk estimates are based on real-time COVID19 surveillance data. They represent estimates given:

- Current reported incidence [CI] (●)
- 5 times the current incidence (▲)
- 10 times the current incidence (■)

These estimates help understand the effects of potential under-testing and reporting of COVID19 incidence.
Initial Covid-19 Vaccine Results Are Positive

- Preliminary results from the first human study of Moderna Inc.'s experimental coronavirus vaccine (code-named mRNA-1273) show the vaccine induced an immune response in some of the healthy volunteers who were vaccinated. In addition, the vaccine appears to be generally safe and well-tolerated.

- FDA recently gave Moderna permission to launch the second phase of testing, and the company hopes to start the final phase in July. If the vaccine proves to work safely in subsequent tests, it could be ready for emergency use as early as this fall.
AzPA COVID-19 Testing Training Program

Part 1 covers:
- Video 1 | Intro
- Video 2 | CLIA
- Video 3 | Types of Tests (updated 5-12-20)
- Video 4 | Patient Assessment
- Video 5 | Specimen Collection
- Video 6 | POC tests (updated 5-12-20)
- Video 7 | Biohazard Waste
- Video 8 | Reporting Results
- Video 9 | Other Considerations

Part 2 will cover Billing in more detail once we have all of the info!

Get CLIA WAIVER!
Questions?